Neumora Therapeutic NMRA 深 沪
交易中 10-06 12:11:34 美东时间
0.4986
-0.027
-5.08%
华盛通- 最 高1.65
- 今 开0.5253
- 成交量 28.11万股
- 最 低 0.4717
- 昨 收 0.5253
- 总市值 0
- 52周最高 3.65
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.4717
- 委 比 11.11%
- 总股本 --
- 历史最高 21.00
- 量 比 0.41
- 振 幅 224.31%
- 历史最低 0.4717
- 每 手 1
- 风险率 0.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail
Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts workforce by 35%.
06-16 00:47
Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June
US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech shares jump 2.8%, energy stocks fall 3.5%. Empire State manufacturing index drops to 5.7. Industrial production up 0.1%. Housing market index declines to 35.
06-16 00:01
Dow Jumps Over 600 Points Following US-Iran Peace Deal
US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks down. Trump announces deal, oil futures decline.
06-15 22:08
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment
William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-511 and obesity pipeline potential.
02-18 03:32
Neumora's Alzheimer's Agitation Drug Shows Early Promise
NMRA-511 showed promising results in Phase 1b study for Alzheimer's disease agitation with favorable tolerability and safety profile.
01-06 00:11
This Chevron Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2025-12-01 22:01
瑞穗：核心新药NMRA-861销售有望达12亿美元 上调Neumora(NMRA.US)目标价至5美元
瑞穗分析师Graig Suvannavejh发表研报，将Neumora Therapeutics(NMRA.US)目标价从4美元上调至5美元，并维持“跑赢大盘...
2025-07-21 14:35
Guggenheim Downgrades Neumora Therapeutics to Neutral
Guggenheim analyst Yatin Suneja downgrades Neumora Therapeutics (NASDAQ:NMRA) from Buy to Neutral.
2025-03-10 23:01
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion
2025-03-07 22:03
